ArticleTransplant infectious disease : an official journal of the Transplantation Society
The Role of Belatacept-Use and Senescence on Infectious and Mortality Complications After Kidney Transplantation.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionStudies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept-use to no belatacept-use in KT recipients.
methodsWe included patients with primary KT between January 1, 2018, and December 31, 2022. We compared outcomes between those who received belatacept and those who did not. Cox proportional hazards models were used with belatacept as a time-varying covariate and adjusted for gender, age at transplant, donor type, underlying disease, CMV serostatus, and organ transplant type. Anderson-Gill hazard of the first Cox models was used to examine the recurrence of DNAemia.
resultsOf 401 KT recipients, 25 received belatacept. Belatacept-use had a higher hazard for EBV and CMV first infection (3.71 [95% CI 1.57, 8.72; p = 0.003] and 2.63 [95% CI 1.04, 6.70; p = 0.042], respectively), and for allograft failure (14.5 [95% CI 5.15, 41.0; p < 0.001]) and acute cellular rejection (5.08 [95% CI 2.56, 11.5; p < 0.001]). Each year increase in zage had a higher hazard for first EBV (3.71 [1.01, 1.05]; p = 0.005) and CMV infection (1.02 [1.00, 1.04]; p = 0.019). D+/R- CMV serostatus had a higher hazard for first CMV infection relative to other serostatuses (4.96 [3.14, 7.85]; p < 0.001).
conclusionCareful selection of KT for belatacept-use is recommended in older recipients (≥ 55 years) due to the increased hazard of mortality, CMV, and EBV DNAemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.